NASDAQ · Biotechnology · USD
Avalyn Pharma Inc. (AVLN) Stock Analysis
Avalyn Pharma Inc. (AVLN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
AVLN Key Statistics
As of Oct 21, 2026Trading
- Open
- $24.74
- Previous Close
- $24.63
- Day's Range
- 22.99–25.57
- 52-Week Range
- 22.24–40.17
- Volume
- 209.63K
Valuation
- Market Cap
- $1.11B
- P/E Ratio
- unprofitable
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −2.47
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$85.20M
- Shares Outstanding
- 44.33M
Dividend and dates
- Earnings Date
- November 16, 2026estimated
- Avg Volume
- 241.49K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
Avalyn Pharma Inc. (AVLN) has a market capitalization of $1.11B.
In fiscal 2025, AVLN reported revenue of $0.00.
AVLN Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$85.20M | — |
| 2024 | $0.00 | −$49.74M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$91.29M | −$85.20M | — |
| 2024 | $0.00 | — | −$57.12M | −$49.74M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Raymond James Initiates Coverage On Avalyn Pharma with Outperform Rating, Announces Price Target of $60
BenzingaAvalyn Pharma (AVLN) Following AP02 Phase 1 Data Is Its Valuation Too Pricey
YahooAvalyn Publishes Phase 1 Data Highlighting AP02’s Lung-Targeted Delivery and Encouraging Safety Profile
YahooAvalyn Pharma Says Respiratory Research Publishes Detailed Results From Two Phase 1 Clinical Trials Of AP02 In Healthy Volunteers And Patients With IPF, Validating Inhaled Antifibrotic Approach
BenzingaAvalyn Appoints Robert J. Meyer, MD, to its Board of Directors
YahooAvalyn Pharma Inc. (AVLN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
SeekingAlpha
All 11 articles ↓Show fewer ↑
Avalyn Presents New Data at ERS Congress 2026 Supporting AP01 Lung Distribution and Patient-Centered Trial Design in Pulmonary Fibrosis
YahooAvalyn to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
YahooAvalyn Pharma Reports New Data Showing Predicted Aerosol Distribution Of AP01 And Survey Data Highlighting Patient Perspectives On Participation In Clinical Studies For Idiopathic Pulmonary Fibrosis
BenzingaMorgan Stanley Maintains Overweight on Avalyn Pharma, Raises Price Target to $57
BenzingaAvalyn Pharma Q2 EPS $(0.65) Misses $(0.53) Estimate
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B